Teva announced new positive post hoc data from its Phase 3 SOLARIS trial for TEV-'749, an olanzapine long-acting injectable for schizophrenia, showing long-term stabilization and remission. This data is presented ahead of an anticipated Q4 FDA approval decision, bolstering the drug's potential market entry and Teva's neuroscience pipeline.
Teva Pharmaceuticals presented new post hoc data from its Phase 3 SOLARIS trial for TEV-'749, an investigational long-acting injectable for schizophrenia. The data indicates that the drug maintained stabilization and supported remission in long-term use, which is a significant positive development. This announcement comes just ahead of an anticipated Q4 FDA approval decision, making the positive data a potential catalyst for the stock. For traders, this strengthens the case for TEVA's neuroscience franchise and could lead to a positive short-term reaction if the FDA approval follows, while long-term implications include a new revenue stream and enhanced market position in schizophrenia treatment.